MedPath

Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Phase 2
Completed
Conditions
Neoplasms
First Posted Date
2005-09-14
Last Posted Date
2011-07-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
20
Registration Number
NCT00165451
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

First Posted Date
2005-09-08
Last Posted Date
2017-09-20
Lead Sponsor
University of Ulm
Target Recruit Count
920
Registration Number
NCT00151242
Locations
🇩🇪

Clinical Center of Hematology and Oncology, University Hospital of Düsseldorf, Düsseldorf, Germany

🇦🇹

Department of Hematology/Oncology, University Hospital Innsbruck, Innsbruck, Austria

🇩🇪

Department of Hematology and Oncology, Hospital Essen Süd, Ev. Hospital of Essen-Werden, Essen, Germany

and more 31 locations

Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: Estramustine
Drug: Etoposide
Drug: Paclitaxel
First Posted Date
2005-09-08
Last Posted Date
2015-01-21
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
28
Registration Number
NCT00151060
Locations
🇺🇸

The University of Michigan Comprehensive Cancer, Ann Arbor, Michigan, United States

Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result

Phase 3
Completed
Conditions
Acute Myeloid Leukemia
First Posted Date
2005-09-05
Last Posted Date
2009-02-09
Lead Sponsor
University of Ulm
Target Recruit Count
400
Registration Number
NCT00146120
Locations
🇩🇪

I. Medical Department, City Hospital München-Schwabing, München, Germany

🇩🇪

Centre of Interial Medicine, University of Göttingen, Göttingen, Germany

🇩🇪

Medical Department III of Hematology and Oncology, General Hospital Altona, Hamburg, Germany

and more 19 locations

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Phase 3
Completed
Conditions
Lymphoma, Large-Cell, Diffuse
Interventions
Drug: Rituximab
Drug: Cisplatine
Drug: Etoposide
Drug: Carboplatine
Drug: Cytosine Arabinoside
Drug: Ifosfamide + Mesna
Drug: Dexamethasone
Procedure: Autologous Stem Cell Transplantation
Drug: BCNU
Drug: Cytarabine
Drug: Melphalan
First Posted Date
2005-08-30
Last Posted Date
2019-08-28
Lead Sponsor
Lymphoma Study Association
Target Recruit Count
481
Registration Number
NCT00137995
Locations
🇮🇱

Israel Society of Hematology, Tel-Hashomer, Israel

🇨🇭

Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland

🇫🇮

Hospital district of south west Finland, Turku, Finland

and more 7 locations

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Phase 3
Completed
Conditions
Localized Osteosarcoma
Metastatic Osteosarcoma
Interventions
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride
Drug: Methotrexate
Drug: Etoposide
Other: Quality-of-Life Assessment
Biological: Peginterferon Alfa-2b
Drug: Ifosfamide
Other: Questionnaire Administration
Procedure: Therapeutic Conventional Surgery
First Posted Date
2005-08-24
Last Posted Date
2023-06-07
Lead Sponsor
Children's Oncology Group
Target Recruit Count
1334
Registration Number
NCT00134030
Locations
🇺🇸

Sinai Hospital of Baltimore, Baltimore, Maryland, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States

and more 215 locations

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2005-08-17
Last Posted Date
2008-11-14
Lead Sponsor
Japan Adult Leukemia Study Group
Target Recruit Count
240
Registration Number
NCT00131027
Locations
🇯🇵

Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

First Posted Date
2005-08-03
Last Posted Date
2013-05-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
10
Registration Number
NCT00126191
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1
Terminated
Conditions
Leukemia
First Posted Date
2005-07-28
Last Posted Date
2013-05-03
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
30
Registration Number
NCT00124644
Locations
🇺🇸

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

First Posted Date
2005-07-11
Last Posted Date
2021-11-17
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
524
Registration Number
NCT00118209
Locations
🇺🇸

Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States

🇺🇸

Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States

🇺🇸

Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States

and more 44 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy